Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript - Thomson StreetEvents

Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript

Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript - Thomson StreetEvents
Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript
Published Aug 03, 2023
17 pages (10394 words) — Published Aug 03, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of REGN.OQ earnings conference call or presentation 3-Aug-23 12:30pm GMT

  
Brief Excerpt:

...Operator Welcome to the Regeneron Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Shannon, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded. I will now turn the call over to Ryan Crowe, Vice President, Investor Relations. You may begin. Ryan Crowe ...

  
Report Type:

Transcript

Source:
Company:
Regeneron Pharmaceuticals Inc
Ticker
REGN.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the quarter and on the progress. Just maybe one on the itepekimab interim. Can you share anything on the futility thresholds? And if not specifically, then could you say how it sort of fared relative to BOREAS? Leonard S. Schleifer - Regeneron Pharmaceuticals, Inc. - Co-Founder, President, CEO & Co-Chairman I don't think we have anything specific. This was (inaudible) -- by the Data Safety Monitoring Committee, sort of a standard approach. We're pleased that we passed it. And we will look forward to further data at the end of the study. George D. Yancopoulos - Regeneron Pharmaceuticals, Inc. - Co-Founder, President, Chief Scientific Officer & Co-Chairman Yes. And both we and Sanofi are blinded to that. We only got the go decision from the independent data monitoring committee. So we'll proceed to a final readout for both of those studies.


Question: Luke Davis - RBC Capital Markets, Research Division - Analyst : This is Luke on for Brian. Can you just provide a little bit more color on what drove the Libtayo growth this quarter? Was there any stocking? Or was it largely demand-based? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 03, 2023 / 12:30PM, REGN.OQ - Q2 2023 Regeneron Pharmaceuticals Inc Earnings Call

Table Of Contents

Regeneron Pharmaceuticals Inc Q3 2023 Earnings Call Summary – 2023-11-02 – US$ 54.00 – Edited Brief of REGN.OQ earnings conference call or presentation 2-Nov-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-11 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 11-Sep-23 1:20pm GMT

Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Summary – 2023-09-06 – US$ 54.00 – Edited Brief of REGN.OQ presentation 6-Sep-23 12:45pm GMT

Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript – 2023-09-06 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 6-Sep-23 12:45pm GMT

Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary – 2023-08-03 – US$ 54.00 – Edited Brief of REGN.OQ earnings conference call or presentation 3-Aug-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Summary – 2023-06-14 – US$ 54.00 – Edited Brief of REGN.OQ presentation 14-Jun-23 3:40pm GMT

Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript – 2023-06-14 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 14-Jun-23 3:40pm GMT

Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Summary – 2023-06-07 – US$ 54.00 – Edited Brief of REGN.OQ presentation 7-Jun-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript – 2023-06-07 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 7-Jun-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Summary – 2023-05-30 – US$ 54.00 – Edited Brief of REGN.OQ presentation 30-May-23 4:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript" Aug 03, 2023. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Regeneron-Pharmaceuticals-Inc-Earnings-Call-T15648282>
  
APA:
Thomson StreetEvents. (2023). Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript Aug 03, 2023. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Regeneron-Pharmaceuticals-Inc-Earnings-Call-T15648282>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.